Risk factors for purulent vaginal discharge and its association with reproductive performance of lactating Jersey cows.

Despite the rapid growth in popularity of the Jersey breed, most research on dairy cows in the United States has been done with the Holstein breed. Postpartum uterine diseases negatively influence reproductive performance of dairy cows and limited data are available regarding predisposing factors for uterine diseases in Jersey cows. Our objectives were to determine the prevalence and risk factors for purulent vaginal discharge (PVD) and its effect on fertility of lactating Jersey cows. This was a retrospective observational study with data collected from 3,822 Jersey cows. The Metricheck device was used for PVD diagnosis, and positive cases (≥50% of pus in exudate) were further classified for severity using the following 4 categories based on the amount of pus observed: 50 to 60% pus in exudate, 60 to 90% pus in exudate, 90 to 100% pus in exudate, and 90 to 100% pus in exudate + uterine fluid detected by palpation per rectum. Univariable and multivariable regression analyzes were conducted to dissect the risk factors for PVD and severity of PVD in Jerseys cows. The major risk factors for PVD were calving-related problems, retained fetal membrane, metritis, and days in the close-up diet. A subgroup of cows (n = 740) was scored for body condition and locomotion scores and had blood sampled in the peripartum for determination of plasma concentrations of nonesterified fatty acids and ß-hydroxybutyrate. In the multivariable analysis that considered data collected for the subgroup of cows, peripartum nonesterified fatty acids, postpartum ß-hydroxybutyrate, and peripartum locomotion and body condition scores were not retained in the reduced model of predictors of PVD. Not surprisingly, pregnancy per artificial insemination following the first and second services was reduced in cows diagnosed with PVD compared with cows without PVD. In addition, PVD was associated with increased odds of pregnancy loss after the first service and reduced hazard of pregnancy by 305 d in milk. The stratification of PVD severity according to the amount of pus observed and the consistency of the uterus was meaningful, as observed by the differences in reproductive outcomes between cows with diverging amounts of pus in the retrieved exudate. Risk factors for PVD in Jersey cows was similar to previously reported for Holstein cows, and a strong detrimental effect of PVD on fertility was also observed in Jersey cows.

Effect of Gammulin supplementation during the first 24 d of life on health, growth, and first-lactation performance of Holstein cows.

Development and health during calfhood are paramount for the success of dairy operations because they are associated with longevity and productivity later in life. Thus, provision of nutritional supplements has been explored as an alternative to improve growth of preweaned calves. Holstein calves (female = 472, male = 46) from 2 dairies located in the San Joaquin Valley were assigned randomly to receive 25 g/d of Gammulin (APC Inc.) from 2 to 24 d of age (GAM = 263) or to receive no supplementation (control = 255). Calves were fed a mixture of waste milk and milk replacer (3.79 L/d), and study personnel added the supplement to the bottles of calves in the GAM treatment daily. Study personnel monitored calves 6 d/wk and recorded starter intake, fecal score (1 = firm, 4 = watery), and attitude score (1 = alert and responsive, 4 = recumbent). Blood samples were collected (4, 7, 14, 26, 44, 56, and 68 d of age) to determine concentrations of total protein, glucose (n = 64), nonesterified fatty acids (n = 64), ß-hydroxybutyrate (n = 171), and hematocrit (n = 518). Calves (n = 64) were treated with 0.5 mg of ovalbumin at 3, 21, and 42 d of age, and concentration of anti-ovalbumin IgG was measured. The percentage of polymorphonuclear leukocytes positive for phagocytosis and oxidative burst after the ex vivo exposure to an enteropathogenic Escherichia coli was evaluated (n = 64). We followed the female calves through the end of the first lactation or until they left the herd to evaluate the effect of treatment on first-lactation performance. Treatment did not affect metabolic and immune responses. During the supplementation (1 to 24 d of age), starter intake did not differ between treatments, but the GAM treatment reduced starter intake (638.5 ± 1.1 vs. 696.6 ± 1.1 g/d; mean ± standard error of the mean) from 25 to 60 d of age and average daily gain (798.8 ± 15.4 and 749.5 ± 15.2) from 23 to 60 d of age, resulting in reduced body weight at 60 d of age (68.4 ± 0.4 vs. 69.8 ± 0.5 kg). From 1 to 24 d of age, GAM treatment reduced the number of days calves had fecal score = 4 (ratio of number of days = 0.92; 95% confidence interval = 0.84-1.00) and it reduced the number of electrolyte treatments calves received (ratio of number of treatments = 0.92; 95% confidence interval = 0.85-0.99). Treatment did not affect the hazard of first calving and first-lactation 305-d milk yield, but the adjusted hazard ratio (0.82; 95% confidence interval = 0.65, 1.04) of pregnancy in the first lactation tended to be reduced for the GAM treatment. In the conditions of this experiment, supplementation with 25 g/d of GAM to the liquid feed from 2 to 24 d of age did not improve calfhood health and performance.

Presynchronization strategy using prostaglandin F2α, gonadotropin-releasing hormone, and detection of estrus to improve fertility in a resynchronization program for dairy cows.

Objectives of experiment 1 were to evaluate pregnancy outcomes and reinsemination patterns of cows whose estrous cycles or ovulation were presynchronized with prostaglandin (PGF2α) or PGF2α and gonadotropin-releasing hormone (GnRH) after non-pregnancy diagnosis in programs focusing on inseminating cows based on tail paint removal. Objectives of experiment 2 were to evaluate pregnancy outcomes and reinsemination patterns of cows with or without a corpus luteum (CL) present at non-pregnancy diagnosis in a program utilizing PGF2α and GnRH to presynchronize estrous cycles before resynchronization. Lactating Holstein cows from three herds were enrolled in the experiments at non-pregnancy diagnosis (d 0). Estrus was determined daily based on tail paint removal. In experiment 1, cows were assigned randomly to two treatments: (1) PGF2α on d 0 (n = 967; P7); and 2) PGF2α on d 0 and GnRH on d 7 (n = 962; P7G7). Cows not reinseminated based on tail paint removal were submitted to the timed-AI Cosynch-72 protocol 7 d after presynchronization treatments. Pregnancy per AI (P/AI) was greater (P = 0.01) for P7G7 cows than P7 cows. Cows inseminated based on tail paint removal had increased (P < 0.01) P/AI than cows submitted to the timed AI protocol. In addition, an interaction was detected (P = 0.03) between method of insemination and presynchronization treatment such that cows submitted to timed AI in the P7G7 treatment had greater P/AI than P7 cows. Nonetheless, P7 cows were inseminated at a faster rate (P < 0.01) than P7G7 cows. In experiment 2, presence of a CL was determined by transrectal ultrasonography at initiation of the P7G7 protocol (n = 1479). In a random subset of cows (n = 210), blood samples were collected immediately after ultrasound examination to determine progesterone concentration in order to evaluate accuracy of detection of a CL by ultrasonography. Accuracy of detection of a CL was 80%. Hazard to insemination and P/AI did not differ among cows regardless of CL status. In conclusion, herds relying mostly on detected estrus to reinseminate cows may achieve greater pregnancy outcomes if presynchronizing with PGF2α and GnRH instead of only PGF2α, albeit at a slower insemination rate. In addition, pregnancy outcomes and reinsemination patterns were similar for cows bearing or not bearing a CL when utilizing the P7G7 protocol, indicating a limited benefit of evaluating ovarian luteal structures by ultrasonography.

Dose frequency of prostaglandin F2α administration to dairy cows exposed to presynchronization and either 5- or 7-day Ovsynch program durations: Ovulatory and luteolytic risks.

We hypothesized (1) that neither duration of the Ovsynch program nor dose frequency of PGF2α would change the proportion of cows with complete luteolysis (progesterone <0.4 ng/mL 72 h after PGF2α) and (2) that the additional GnRH treatment administered as part of a presynchronization program would not alter the proportion of anovulatory cows starting the timed artificial insemination (AI) program compared with an alternative shorter presynch program including only 1 GnRH treatment. Lactating Holstein cows (n = 406) were milked 3 times daily and enrolled in a 2 × 2 × 2 factorial experiment consisting of 8 treatments before the first postpartum AI. Treatments were used to test ovulatory, luteal, and luteolytic outcomes to 3 main effects: (1) 2 GnRH-PGF2α presynchronization programs (PG-3-G vs. Double Ovsynch), (2) 2 Ovsynch program durations [5 d: GnRH (GnRH-1)-5 d-PGF2α-24 h-PGF2α-32 h-GnRH (GnRH-2)-16 h-timed AI; 7 d: GnRH-1-7 d-PGF2α-56 h-GnRH-2-16 h-timed AI], and (3) 2 PGF2α dose frequency treatments (2 × 25 mg) 24 h apart versus 1 dose (1 × 50 mg) of PGF2α administered 72 h before timed AI. The presynchronization treatments of PG-3-G and Double Ovsynch had no effect on the proportion of cows with luteal function at the onset of the Ovsynch treatments (87.9 vs. 86.2%). Although ovulatory responses were similar after GnRH-1 (>60%), Double Ovsynch cows tended to have greater ovulatory responses than PG-3-G after GnRH-2 (95.3 vs. 90.6%). The 2 × 25-mg doses of PGF2α and the 1 × 50-mg dose induced luteolysis in both Ovsynch treatment durations, but the 1 × 50-mg dose was less effective in the 5-d program. More pregnancy per AI (P/AI; 49.2%) tended to occur in the PG-3-G cows in the 7-d program compared with the other treatment combinations (range: 32.4-37.4%; Ovsynch × presynch interaction). In addition, an Ovsynch × PGF2α dose frequency interaction resulted in cows receiving the 1 × 50-mg dose in the 7-d program having the greatest P/AI (46.1%) and cows receiving the 1 × 50-mg dose in the 5-d program having the least P/AI (30.6%). We conclude that complete luteolysis was less effective in the 5-d program when the 1 × 50-mg dose was applied, but both PGF2α dose frequencies (1 × 50 mg and 2 × 25 mg 24 h apart) effectively induced complete luteolysis in the 7-d program. Treatments producing complete luteolysis tended to be related to subsequent pregnancy outcomes.

Response of lactating dairy cows with or without purulent vaginal discharge to gonadotropin-releasing hormone and prostaglandin F2α.

Purulent vaginal discharge (PVD) is a common uterine disease in dairy cattle that has negative effects on reproductive performance. Reproductive management programs that synchronize ovulation use gonadotropin-releasing hormone (GnRH) to induce ovulation and prostaglandin F2α (PGF2α) to induce luteolysis. The objectives of this study were to evaluate ovarian response to treatment with GnRH and the odds of bearing a corpus luteum or being inseminated in dairy cows with or without PVD. Another objective was to determine the hazard of insemination after administration of PGF2α in dairy cows with or without PVD. Primiparous (n = 291) and multiparous (n = 402) cows were evaluated for PVD using a Metricheck device at 46 ± 3 and 35 ± 3 days in milk (DIM) (study day 0), respectively. On study day 14, primiparous (n = 107) and multiparous (n = 197) cows were treated with GnRH and subsequent ovulation was recorded. Primiparous (n = 178) and multiparous (n = 368) cows not inseminated by study day 21 were administered PGF2α and response to PGF2α treatment was determined by detection of estrus. Furthermore, cows were categorized by the presence of a CL or being inseminated by study days 14, 21, and 35. Overall prevalence of PVD was 28.5% and 13.4% for primiparous and multiparous cows, respectively. Projected 305-d milk yield was less (P < 0.01) in PVD+ multiparous cows compared with PVD- multiparous cows, however, no (P = 0.26) difference was detected between primiparous PVD+ and PVD- cows. Ovulatory response to GnRH treatment was 51.8% and 47.8% for primiparous and multiparous cows, respectively. Primiparous PVD- cows tended (P = 0.06) to be less likely to ovulate to GnRH than primiparous PVD+ cows, whereas multiparous PVD+ cows were less (P = 0.04) likely to ovulate to GnRH than PVD- multiparous cows. The odds of bearing a corpus luteum or being inseminated by study days 14, 21, or 35 was not associated with PVD in primiparous cows. In contrast, the odds of bearing a corpus luteum or being inseminated by study days 14 and 21 was (P ≤ 0.03) associated with PVD in multiparous cows, but not (P = 0.11) on study day 35. Hazard of insemination after PGF2α was not (P ≥ 0.38) associated with PVD in primiparous or multiparous cows. Purulent vaginal discharge is associated with response to treatment with GnRH in dairy cattle. Purulent vaginal discharge might negatively affect reproductive management programs that use GnRH to induce ovulation.

Additional small dose of prostaglandin F2α at timed artificial insemination failed to improve pregnancy risk of lactating dairy cows.

Two experiments were performed to test the hypothesis that administering PGF2α concurrent with timed artificial insemination (AI) in lactating dairy cows would enhance pregnancy per AI (P/AI). In experiment 1, lactating Holstein cows (n = 289) in one herd were enrolled after a non-pregnancy diagnosis (30-36 d after AI) to synchronize subsequent ovulation before AI. Cows were assigned randomly to receive (im) 10 mg of PGF2α concurrent with timed AI (Day 0; treatment) or no injection (control). Blood samples were collected on Days -3, 0, and 13 to determine serum concentrations of progesterone. Ovaries were scanned via transrectal ultrasonography to determine follicle diameters (Day -3), subsequent ovulation risk (Day 13), and total volume of luteal tissue (Day 13). Diagnosis of pregnancy occurred on Days 32 and 80 after AI. Ovulation risk post-AI exceeded 90% and did not differ between treatments. In addition, PGF2α treatment only numerically increased progesterone (5.7 ±â€¯0.3 vs. 6.2 ±â€¯0.3 ng/mL) or luteal tissue volume (8.9 ±â€¯0.4 vs. 9.8 ±â€¯0.5 ng/mL) on Day 13 by 8.8% (P = .206) or 10.1% (P = .134) in control and treated cows, respectively. Pregnancy per AI at Days 32 (P = .50) and 80 (P = .33) did not differ between treatments. Cows with progesterone >0.5 ng/mL at timed AI had reduced (P < .001) ovulation risk but risk was unaffected by treatment. In experiment 2, lactating dairy cows (n = 1828) in two commercial dairy herds were enrolled at time of insemination (Day 0), and assigned randomly to treatment or control as described in experiment 1. Initial (Days 32-35) and confirmed (Days 63-68) pregnancy diagnosis revealed no differences in P/AI or pregnancy loss. Pregnancy diagnosis on Days 32-35 produced percentage increases in P/AI for primiparous compared with multiparous cows (20.8%; P = .002), for first-service compared with repeat-service cows (26%; P = .001), and cows in one herd compared with the second herd (36%; P < .001). Pregnancy loss was greater (P = .001) for cows inseminated at first (10.0%) vs. later services (5.3%) but was unaffected by treatment. Cows treated with PGF2α in one herd produced more twins than control cows (11.7 vs. 3.2%), whereas no treatment difference was detected in the second herd (5.6 vs. 5.6%), respectively. We conclude that im treatment of lactating dairy cows with 10 mg of PGF2α concurrent with timed AI did not improve P/AI or embryo survival, but increased twinning in one herd.

Fertility of lactating dairy cows treated with gonadotropin-releasing hormone at AI, 5 days after AI, or both, during summer heat stress.

Objectives of this experiment were to evaluate pregnancy per AI (P/AI) and progesterone (P4) concentrations after AI of lactating dairy cows under heat stress conditions treated with 100 µg gonadotropin-releasing hormone (GnRH) at AI, 5 d after AI, or both. Lactating Holstein cows from two herds were enrolled in the study during summer. Cows detected in estrus based on tail paint removal were allocated to four treatments: (1) control (CON = 722); (2) GnRH treatment at AI (G0 = 739); (3) GnRH treatment 5 d post-AI (G5 = 697); or (4) GnRH treatment at AI and 5 d post-AI (G0+G5 = 697). Blood samples were collected from a subgroup of cows at AI (study d 0), study d 5 and 12 to determine P4 concentrations. Pregnancy diagnosis was conducted at study d 36 and 94. Temperature and relative humidity were collected from a meteorological station nearest the herds and temperature-humidity index (THI) was calculated. Average THI during study enrollment was 83.8 ± 0.1 and THI at study d 0 tended (P = 0.09) to be associated with P/AI at study d 36, but it was not (P = 0.33) associated with P/AI at study d 94. Treatment with GnRH at AI, 5 d after AI, or both, did not affect (P ≥ 0.64) P/AI at study d 36 or 94. An interaction, however, was detected (P = 0.06) between treatment and lactation number. Such an interaction was observed because, among ≥ third-lactation cows, P/AI was greater for G0+G5 (28.6%) and G5 (25.3%) than CON cows (17.3%) at study d 36. Pregnancy per AI of ≥ third-lactation G0 cows did not (P ≥ 0.11) differ from CON, G5, and G0+G5 cows. No differences in P/AI were detected among treatments in first- and second-lactation cows. Overall, treatments with GnRH at AI, 5 d after AI, or both were not (P = 0.94) associated with P4 concentrations on study d 0, 5 or 12. Among cows diagnosed pregnant at study d 36, progesterone concentration on d 5 was not affected (P ≥ 0.24) by treatments with GnRH at AI, 5 d after AI, or both, but progesterone concentration on d 12 was greater for cows treated with GnRH at AI and 5 d after AI compared with G0 cows. Lactating dairy cows in their third or greater lactation exposed to heat stress conditions with compromised fertility may have increased P/AI after treatment with GnRH 5 d after AI or the combined treatment of GnRH at AI and 5 d after AI because of reduced early embryonic loss.

Association between 4-day vaginal temperature assessment during the dry period and performance in the subsequent lactation of dairy cows during the warm season.

The objective of the study was to investigate the relationships between vaginal temperature during the dry-period and health, milk production, and reproduction in the subsequent lactation of cows during the warm season. A total of 105 nonlactating Holstein cows from 2 dairies were enrolled in the study during summer. At enrollment, cows were between 250 and 260 d of gestation. Vaginal temperature (VT) and corral ambient temperature and humidity were recorded every 5 min for 4 consecutive days starting at enrollment. Cows were categorized as presenting high (HT) or low temperature (LT) based on the median values of average VT and were followed until 300 d in milk (DIM) of the subsequent lactation to evaluate health disorders, culling rate, milk yield, and reproductive efficiency. Cows that became pregnant were followed until subsequent calving. Cows were monitored for uterine diseases (UTD) and mastitis (MAST) by farm personnel. Individual milk yield was recorded monthly until 300 DIM. Cows classified as HT had shorter ( < 0.01) gestation length (273.9 ± 0.9 vs. 278.7 ± 1.0 d) and spent fewer ( < 0.01) days in the close-up pen (14.3 ± 0.8 vs. 19.4 ± 1.0 d) than LT cows. Hazard to UTD or MAST in the first 60 DIM was greater for HT than LT cows (adjusted hazard ratio [AHR] = 5.15, 95% CI = 1.91 to 13.86). Cows classified as HT had greater hazard to MAST in the first 300 DIM compared with LT cows (AHR = 2.39; 1.03 to 5.56). Vaginal temperature was not associated with milk yield. In contrast, the interaction between VT category and month of lactation tended to influence milk yield. This interaction was observed because cows categorized as LT had greater ( < 0.01) milk yield in the first month of lactation compared with HT cows (39.2 ± 1.6 vs. 33.7 ± 1.5 kg), whereas milk yield tended ( = 0.07) and was greater ( = 0.05) for HT cows in the ninth (32.7 ± 1.6 vs. 28.5 ± 1.9 kg) and tenth (29.9 ± 1.7 vs. 25.0 ± 2.0 kg) month of lactation, respectively. Pregnancy per AI at first service, interval from calving to pregnancy, and percentage of cows calving in the subsequent lactation did not differ between HT and LT cows. In conclusion, VT assessed between 20 and 30 d before expected calving is associated with health outcomes and milk production in the subsequent lactation. In addition, cows susceptible to be affected by postpartum disorders after calving may be identified during the summer by evaluating VT temperature at 250 to 260 d of gestation.

Increasing estrus expression in the lactating dairy cow.

Using an activity monitoring system (AMS) equipped with an accelerometer, 2 experiments were conducted to test the hypotheses that (1) enhancing progesterone before inducing luteolysis or (2) exposing cows to estradiol cypionate (ECP) or testosterone propionate (TP) after luteolysis would increase occurrence and intensity of estrus. Our goal was to determine if more cows could be detected in estrus by an AMS compared with other estrus-detection aids. In experiment 1, cows (n=154) were fitted with both an AMS collar and a pressure-sensitive, rump-mounted device (HeatWatch; HW) and assigned to 3 treatments: (1) no CL + progesterone insert (CIDR) for 5d, (2) CL only, or (3) CL + 2 CIDR inserts for 5d to achieve a range in concentrations of progesterone. Prostaglandin F2α was administered to all cows upon CIDR insert removal or its equivalent. Progesterone concentration up to 72h posttreatment was greatest in CL + 2 CIDR, followed by CL only, and no CL + CIDR cows. Estrus occurred 14 to 28h earlier in no CL + CIDR compared with CL-bearing cows. Estrus intensity was greater for CL + 2 CIDR than for CL-only cows. The AMS and HW detected 70 and 59% of cows defined to be in estrus, respectively. In experiment 2, cows (n=203) were equipped with both an AMS and a friction-activated, rump-mounted patch (Estrotect patch) and assigned to receive 1mg of ECP, 2mg of TP, or control 24h after PGF2α. Concentrations of estradiol 24 and 48h after treatment were greater in ECP cows compared with controls. Estrus expression detected by AMS or patches in cows defined to be in estrus tended to be greater or was greater for ECP compared with controls, respectively. Compared with controls and in response to TP or ECP, estrus occurred 8 to 18h earlier and was of greater intensity for ECP cows, respectively. The AMS and patches determined 73 and 76% of cows defined to be in estrus, respectively. Of cows exposed to the AMS, HW, or patches, 70, 61, and 75%, respectively, were detected in estrus and more than 93% of these subsequently ovulated. In contrast, of the residual cows not detected in estrus, 62 to 77% ovulated in the absence of detected estrus. Only ECP was successful in inducing more expression and intensity of estrus, and proportions of cows detected in estrus exceeded 80%. Given the large proportion of cows equipped with AMS collars ovulating in the absence of estrus, further research is warranted to determine if more pregnancies can be achieved by inseminating those cows not detected in estrus at an appropriate time when PGF2α is administered to induce luteolysis.

Treatment of lactating dairy cows with gonadotropin-releasing hormone before first insemination during summer heat stress.

The objectives of the experiments were to compare ovarian responses, pregnancy per artificial insemination, and pattern of insemination of 2 estrus detection-based presynchronization protocols before first artificial insemination (AI) during heat stress. In experiment 1, primiparous lactating dairy cows (n=1,358) from 3 dairies were assigned randomly to 2 treatments at 60±3 (±SD) DIM (study d 0): (1) treatment with 100 µg of GnRH on study d 0 (Gpresynch), or (2) no treatment on study d 0 (control). In experiment 2, multiparous lactating dairy cows (n=1,971) from 3 dairies were assigned randomly to 2 treatments at 49±3 (±SD) DIM (study d 0), similar to experiment 1. In both experiments, PGF2α injections were administered 14 d apart starting on study d 7 for all cows. Cows not inseminated after detection of estrus were submitted to a timed artificial insemination protocol at study d 35. In a subgroup of cows from 2 dairies, concentrations of progesterone were determined from blood samples collected on study d 0 and 7. Furthermore, ovaries were examined by ultrasonography on study d -14, 0, and 7 to determine cyclic status and ovulation in response to GnRH treatment. In experiment 1, progesterone concentration was not different on d 0, but progesterone was increased for Gpresynch compared with control cows on study d 7 (3.6±0.3 vs. 2.7±0.4 ng/mL), respectively. Ovulation risk from study d 0 to 7 was increased for Gpresynch compared with control (50.6 vs. 15.2%). Control cows were inseminated at a faster rate than Gpresynch cows [adjusted hazard ratio (AHR)=0.89, 95% confidence interval=0.80 to 1.00], and the interaction between treatment and dairy affected pregnancy per artificial insemination at 36 and 94 d post-artificial insemination. In experiment 2, concentrations of progesterone did not differ on study d 0 or 7, despite ovulation risk from study d 0 to 7 being greater in Gpresynch than control cows (46.9 vs. 23.8%). The interaction between treatment and dairy affected hazard of insemination with Gpresynch cows from dairy 1 (AHR=1.21; 1.05 to 1.41) being inseminated faster than control cows. Hazard of pregnancy was affected by treatment because Gpresynch cows became pregnant at a faster rate than control cows (AHR=1.25; 1.04 to 1.50). In conclusion, GnRH-based presynchronization protocols initiated before the end of the voluntary waiting period may have benefits in reproductive efficiency of estrus detection-based programs during heat stress. In addition, treatment with GnRH decreased the prevalence of anovular cows at the initiation of PGF2α injections.

Hot topic: Early postpartum treatment of commercial dairy cows with nonsteroidal antiinflammatory drugs increases whole-lactation milk yield.

Previous research has shown that postpartum administration of the nonsteroidal antiinflammatory drug (NSAID) sodium salicylate can increase 305-d milk yield in older dairy cattle (parity 3 and greater). However, in this prior work, sodium salicylate was delivered to cows via the drinking water, a method that does not align well with current grouping strategies on commercial dairy farms. The objective of the current study was to replicate these results on a commercial dairy farm with a simplified treatment protocol and to compare sodium salicylate with another NSAID, meloxicam. Dairy cattle in their second lactation and greater (n=51/treatment) were alternately assigned to 1 of 3 treatments at parturition, with treatments lasting for 3d. Experimental treatments began 12 to 36 h after parturition and were (1) 1 placebo bolus on the first day and 3 consecutive daily drenches of sodium salicylate (125 g/cow per day; SAL); (2) 1 bolus of meloxicam (675 mg/cow) and 3 drenches of an equal volume of water (MEL); or (3) 1 placebo bolus and 3 drenches of water (CON). Blood samples were collected on the first day of treatment, immediately following the last day of treatment, and 7d after the last day of treatment; plasma was analyzed for glucose, ß-hydroxybutyrate (BHB), free fatty acids, haptoglobin, and paraoxonase. Milk production, body condition score, reproductive status, and retention in the herd were monitored for 365 d posttreatment, and effects of treatment, parity, days in milk, and interactions were evaluated in mixed effects models. Significance was declared at P<0.05. Whole-lactation milk and protein yields were greater in NSAID-treated cows, although 305-d fat production was not affected. There was a significant interaction of treatment and parity for plasma glucose concentration; MEL increased plasma glucose concentrations compared with CON and SAL in older cows. Sodium salicylate decreased plasma BHB concentration compared with MEL at 7d posttreatment, although no difference was detected immediately following treatment. Haptoglobin concentrations were elevated in SAL cows compared with CON. There was a tendency for CON cows to be removed from the herd more quickly than MEL cows (42 vs. 26% at 365 d posttreatment). Body condition score, concentrations of plasma free fatty acids and paraoxonase, and time to pregnancy were not affected by treatment. These results indicate that NSAID administration in postpartum cows has the potential to be a viable way to improve productivity and potentially longevity in commercial dairies, although further research is necessary to optimize recommendations for producers.

Short communication: Insertion of an intravaginal progesterone device at the time of gonadotropin-releasing hormone (GnRH) injection affects neither GnRH-induced release of luteinizing hormone nor development of dominant follicle in early diestrus of lactating dairy cows.

Our objectives were to evaluate the acute effects of a controlled internal drug release (CIDR) insert containing 1.38 g of progesterone (P4) on the release of LH, follicular growth, and circulating concentrations of P4 in cows treated with GnRH at the time of CIDR insertion. Nonpregnant, lactating dairy cows (n=27) were blocked by parity, predicted 305-d mature-equivalent milk production, and body condition score and randomly assigned to 1 of 3 treatments: (1) CIDR insertion concurrent with an injection of 200 µg of GnRH (n=10; 2GP4); (2) CIDR insertion concurrent with an injection of 100 µg of GnRH (n=10; 1GP4); and (3) injection of 100 µg of GnRH (n=7; CON). Prior to onset of treatments, cows were submitted to a presynchronization protocol that consisted of a CIDR insert containing 1.38 g of P4 from d -7 to -2, 25mg of PGF2α on d -2 and -1, and 100 µg of GnRH on d 0. Experimental treatments were applied on d 6, the early luteal phase of the estrous cycle. Concentrations of P4 in plasma were determined on d -2 and 0 and at 0, 15, 30, 60, 120, 240, 345, 600, and 1,200 min relative to treatment on d 6. Concentrations of LH were determined in plasma samples obtained at 0, 15, 30, 60, 120, 240, and 345 min relative to treatment on d 6. Ultrasonography examinations of ovarian structures were performed on d -2, 0, 2, and at 0, 600, and 1,200 min relative to treatment on d 6. Mean concentrations of P4 in the CON group (1.91±0.28 ng/mL) were lower than in 2GP4 (3.40±0.26 ng/mL) and 1GP4 (3.31±0.24 ng/mL) groups, but concentrations in 2GP4 and 1GP4 were similar. Mean concentration of LH in response to the GnRH injection on d 6 was greatest in 2GP4 cows (3.08±0.21 ng/mL) and did not differ between 1GP4 (2.23±0.21 ng/mL) and CON (2.14±0.25 ng/mL) cows. The diameter of the dominant follicle on d 6 was similar among treatments (2GP4=15.34±0.50; 1GP4=15.31±0.50; CON=14.77±0.62 mm). In conclusion, CIDR insertion concurrent with a 100- or 200-µg dose of GnRH neither altered GnRH-induced LH release nor had an acute effect on dominant follicle growth.

Yeast product supplementation modulated humoral and mucosal immunity and uterine inflammatory signals in transition dairy cows.

The transition from late gestation to early lactation is characterized by substantial metabolic stress and altered immune function. The objective of this study was to assess the effects of supplementing a yeast product derived from Saccharomyces cerevisiae on immunity and uterine inflammation in transition cows. Forty multiparous Holstein cows were blocked by expected parturition date and randomly assigned within block to 1 of 4 treatments (n=10) from 21d before expected parturition to 42d postpartum. Rations were top-dressed with a product containing yeast culture plus enzymatically hydrolyzed yeast (YC-EHY; Celmanax, Vi-COR, Mason City, IA) at the rate of 0, 30, 60, or 90g/d throughout the experiment. Cows were injected subcutaneously with ovalbumin on d -21, -7, and 14 to assess their humoral response. Data were analyzed using mixed models with repeated measures over time. Concentrations of colostrum IgG were unaffected by treatments. A treatment × week interaction was observed for somatic cell linear score, reflecting a tendency for a quadratic dose effect on wk 1 (2.34, 2.85, 1.47, and 4.06±0.59 for 0, 30, 60, and 90g/d, respectively) and a quadratic dose effect on wk 5 (1.36, -0.15, -1.07, and 0.35±0.64 for 0, 30, 60, and 90g/d, respectively). Platelet count was increased by YC-EHY. Increasing YC-EHY dose linearly increased plasma anti-ovalbumin IgG levels following 3 ovalbumin challenges, suggesting that treatments enhanced humoral immunity. Increasing YC-EHY dose also quadratically increased fecal IgA concentrations in early lactation, suggesting that 30 and 60g/d doses enhanced mucosal immunity. Uterine neutrophil populations were much greater in samples collected on d 7 compared with those on d 42 (32.1 vs. 7.6±3.5% of cells), reflecting neutrophil infiltration immediately after calving, but no treatment effect was detected. Significant day effects were detected for mRNA of IL-6, IL-8, neutrophil myeloperoxidase (MPO), and neutrophil elastase (ELANE) in the uterine samples, reflecting greater abundance of these transcripts collected on d 7 compared with d 42. A quadratic dose effect was detected for IL-6, indicating that 30 and 60g/d doses decreased uterine IL-6 mRNA. The mRNA abundance of MPO and ELANE was increased linearly by YC-EHY. Supplementation with YC-EHY enhanced measures of humoral and mucosal immunity and modulated uterine inflammatory signals and mammary gland health in transition dairy cows.

Yeast product supplementation modulated feeding behavior and metabolism in transition dairy cows.

Yeast supplementation has been shown to increase feed intake and production in some studies with early lactation dairy cows, but the mechanisms underlying such an effect remain unknown. The objective of this study was to assess the effects of supplementing a yeast product derived from Saccharomyces cerevisiae on production, feeding behavior, and metabolism in cows during the transition to lactation. Forty multiparous Holstein cows were blocked by expected calving date and randomly assigned within block to 1 of 4 treatments (n=10) from 21 d before expected calving to 42 d postpartum. Rations were top-dressed with a yeast culture plus enzymatically hydrolyzed yeast (YC-EHY; Celmanax, Vi-COR Inc., Mason City, IA) at the rate of 0, 30, 60, or 90g/d throughout the experiment. Dry matter and water intake, feeding behavior, and milk production were monitored. Plasma samples collected on -21, -7, 1, 4, 7, 14, 21, and 35 d relative to calving were analyzed for glucose, ß-hydroxybutyrate, and nonesterified fatty acids. Data were analyzed using mixed models with repeated measures over time. Pre- or postpartum dry matter intake and water intake did not differ among treatments. Quadratic dose effects were observed for prepartum feeding behavior, reflecting decreased meal size, meal length, and intermeal interval, and increased meal frequency for cows received 30 and 60g/d of YC-EHY. Postpartum feeding behavior was unaffected by treatments. Milk yields were not affected (45.3, 42.6, 47.8, and 46.7kg/d for 0, 30, 60, and 90g/d, respectively) by treatments. Tendencies for increased percentages of milk fat, protein, and lactose were detected for cows receiving YC-EHY. Supplementing YC-EHY increased plasma ß-hydroxybutyrate and tended to decrease (quadratic dose effect) glucose but did not affect nonesterified fatty acids. Yeast product supplementation during the transition period did not affect milk production and dry matter intake but modulated feeding behavior and metabolism.

Effect of an Ovsynch56 protocol initiated at different intervals after insemination with or without a presynchronizing injection of gonadotropin-releasing hormone on fertility in lactating dairy cows.

The objectives of this study were to evaluate effects of 2 resynchronization protocols beginning at different intervals after artificial insemination (AI) on the pattern of return to estrus, ovarian responses, and pregnancy per AI (P/AI) to reinsemination. Lactating cows from 2 dairies, located in Texas (n=2,233) and Minnesota (n=3,077), were assigned to 1 of 4 timed AI (TAI) protocols 17 ± 3 d after AI. All cows were examined for pregnancy 31 ± 3 d after previous AI. Cows assigned to early Ovsynch56 (E-OV56) or OV56 received the Ovsynch56 protocol starting 24 or 31 d after AI, respectively. Cows assigned to early GnRH-GnRH-PGF(2α)-GnRH (E-GGPG) or GGPG received a presynchronizing GnRH injection 17 or 24 d after AI, respectively, 7 d before the start of the Ovsynch56 protocol. Cows observed in estrus after enrollment were inseminated on the same day. Ovaries were examined and blood was sampled for progesterone concentration on the day of first GnRH and PGF(2α) injection of the Ovsynch56 protocol. Pregnancy was diagnosed at 31 and 66 d after resynchronized AI. On the day of the first GnRH injection of the TAI, a higher percentage of cows on E-GGPG and GGPG protocols had a corpus luteum (E-GGPG=83.8, GGPG=91.2, E-OV56=80.4, and OV56=75.5%) and progesterone concentration >1 ng/mL (E-GGPG=62.5, GGPG=76.0, E-OV56=53.6, and OV56=60.8%) than cows assigned to other protocols. However, the percentage of cows ovulating to the first GnRH injection of TAI was not affected by treatment. Fewer E-GGPG and more OV56 cows were reinseminated in estrus (E-GGPG=23.7, GGPG=49.0, E-OV56=41.6, and OV56=57.6%). Treatment did not affect P/AI at 31 or 66 d for cows reinseminated in estrus. However, cows reinseminated in estrus had greater P/AI at 31 (40.0 vs. 27.5%) and 66 d (36.0 vs. 23.9%) than cows completing the TAI protocols. Among cows completing the TAI protocols, initiation of GGPG at 24 d after AI increased, whereas initiation of Ovsynch56 at 24 d after AI decreased P/AI at 31 d after reinsemination (E-GGPG=30.6, GGPG=28.3.0, E-OV56=22.3, and OV56=28.7%). Pregnancy per AI did not differ across treatment at 66 d after TAI (E-GGPG=26.6, GGPG=24.4, E-OV56=20.0, and OV56=24.1%). Overall, type of resynchronization protocol and protocol initiation time did not affect P/AI 66 d after reinsemination (E-GGPG=29.7, GGPG=30.5, E-OV56=26.1, and OV56=30.4%). In conclusion, GGPG resynchronization protocols and initiation of resynchronization protocol 24 d after AI reduced the number of cows reinseminated in estrus but neither the timing of initiation of resynchronization nor presynchronization with GnRH affected overall P/AI.

Comparison of peripartum metabolic status and postpartum health of Holstein and Montbéliarde-sired crossbred dairy cows.

Objectives of the current experiment were to evaluate plasma concentrations of metabolites and haptoglobin peripartum, uterine health and involution, and follicle growth and resumption of cyclicity of Holstein (HO) and Montbéliarde-sired crossbred cows. Cows (52 HO and 52 crossbred) were enrolled in the study 45 d before expected calving date. Cows had body weight and body condition score recorded on d -45, -14, 0, 1, 28, and 56 relative to calving. Dry matter intake was calculated for a subgroup of cows (25 HO and 38 crossbred) from 6 wk before to 6 wk after calving. Blood was sampled weekly from d -14 to 56 relative to calving for determination of glucose, nonesterified fatty acid, and ß-hydroxybutyrate concentrations; from d -7 to 21 relative to calving for determination of haptoglobin concentration; and from d 14 to 56 postpartum for determination of progesterone concentration. Cows were examined at calving and on d 4, 7, 10, and 14 postpartum for diagnosis of postparturient diseases, on d 24 postpartum for diagnosis of purulent vaginal discharge, and on d 42 postpartum for diagnosis of subclinical endometritis. Uteri and ovaries were examined by ultrasonography every 3 d from d 14 to 41 postpartum. Milk yield and composition were measured monthly and yield of milk, fat, protein, and energy-corrected milk were recorded for the first 90 d postpartum. Body weight was not different between Holstein and crossbred cows, but HO cows had reduced body condition score compared with crossbred cows. Even though DMI from 6 wk before to 6 wk after calving tended to be greater for HO cows (16.8 ± 0.7 vs. 15.3 ± 0.5 kg/d), HO cows tended to have more pronounced decline in dry matter intake, expressed in percentage of body weight from d -15 to 0 relative to calving. Energy-corrected milk and nonesterified fatty acid and ß-hydroxybutyrate concentrations were not different between breeds. No differences were observed in incidence of retained fetal membranes, metritis, and subclinical endometritis, but HO cows tended to be more likely to have pyrexia from d 0 to 15 postpartum (50.0 vs. 31.4%) and to have greater incidence of purulent vaginal discharge (44.2 vs. 26.5%) than crossbred cows. Holstein cows were more likely to have at least 1 uterine disorder postpartum than crossbred cows (63.5 vs. 36.7%). No differences between breeds were observed in uterine involution. Holstein cows had larger subordinate follicles (10.1 ± 0.4 vs. 8.9 ± 0.5) and a greater number of class III follicles (1.6 ± 0.1 vs. 1.2 ± 0.1) than crossbred cows. Furthermore, the first corpus luteum postpartum of HO cows was diagnosed at a slower rate compared with crossbred cows. Crossbred cows had improved uterine health compared with HO cows and this may have been a consequence of heterosis and (or) breed complementarity and less pronounced decrease in DMI during the last days of gestation.

Effects of weekly regrouping of prepartum dairy cows on innate immune response and antibody concentration.

Objectives were to evaluate the effects of a stable prepartum grouping strategy on innate immune parameters, antibody concentration, and cortisol and haptoglobin concentrations of Jersey cows. Cows (253±3 d of gestation) were paired by gestation length and assigned randomly to the stable (all-in-all-out; AIAO) or traditional (TRD) treatment. In the AIAO treatment, groups of 44 cows were moved into a pen where they remained for 5 wk, whereas in the TRD treatment, approximately 10 cows were moved into a pen weekly to maintain stocking density (44 cows for 48 headlocks). Pens were identical in size and design and each pen received each treatment a total of 3 times (6 replicates; AIAO, n=259; TRD, n=308). A subgroup of cows (n=34/treatment) was selected on wk 1 of each replicate from which blood was sampled weekly from d -14 to 14 (d 0=calving) to determine polymorphonuclear leukocyte (PMNL) phagocytosis, oxidative burst, and expression of CD18 and L-selectin, hemogram, cortisol and glucose concentrations, and haptoglobin concentration. Another subgroup of cows (n=40/treatment) selected on wk 1 of each replicate was treated with chicken egg ovalbumin on d -21, -7, and 7 and had blood sampled weekly from d -21 to 21 for determination of immunoglobulin G anti-ovalbumin. All cows (n=149) had blood sampled weekly for nonesterified fatty acid (NEFA) and ß-hydroxybutyrate (BHBA) concentrations from d -21 to 21. Treatment did not affect percentage of PMNL positive for phagocytosis and oxidative burst (AIAO=64.3±2.9 vs. TRD=64.3±2.9%) and intensity of phagocytosis [AIAO=2,910.82±405.99 vs. TRD=2,981.52±406.87 geometric mean fluorescence intensity (GMFI)] and oxidative burst (AIAO=7,667.99±678.29 vs. TRD=7,742.70±682.91 GMFI). Similarly, treatment did not affect the percentage of PMNL expressing CD18 (AIAO=96.3±0.7 vs. TRD=97.8±0.7%) and L-selectin (AIAO=44.1±2.8 vs. TRD=45.1±2.8%) or the intensity of expression of CD18 (AIAO=3,496.2±396.5 vs. TRD=3,598.5±396.9 GMFI) and L-selectin (AIAO=949.8±22.0 vs. TRD=940.4±22.3 GMFI). Concentration of immunoglobulin G anti-ovalbumin was not affected by treatment (AIAO=0.98±0.05 vs. TRD=0.98±0.05 OD). The percentage of leukocytes classified as granulocyte (AIAO=38.9±1.5 vs. TRD 38.2±1.5%) and the granulocyte:lymphocyte ratio (AIAO=0.75±0.04 vs. TRD=0.75±0.04) were not affected by treatment. Concentrations of cortisol (AIAO=14.95±1.73 vs. TRD=18.07±1.73 ng/mL), glucose (AIAO=57.6±1.5 vs. TRD=60.0±1.5 ng/mL), and haptoglobin (AIAO=3.09±0.48 vs. TRD=3.51±0.49 OD) were not affected by treatment. According to the current experiment, a stable prepartum grouping strategy does not improve innate immune parameters or antibody concentration compared with weekly prepartum regrouping.

Effects of weekly regrouping of prepartum dairy cows on metabolic, health, reproductive, and productive parameters.

The objectives of the current experiment were to determine the effect of 2 prepartum grouping strategies on the health, metabolic, reproductive, and productive parameters of dairy cows. Jersey cows enrolled in the experiment at 253±3 d of gestation (d 0=calving) were balanced for parity and projected 305-d mature equivalent and assigned to 1 of 2 treatments. Cows assigned to the traditional (TRD; n=6 replicates with a total of 308 cows) treatment were moved to the study pen as a group of 44 cows and weekly thereafter groups of 2 to 15 cows were moved to the study pen to reestablish stocking density. Cows assigned to the all-in-all-out (AIAO; n=6 replicates with a total of 259 cows) treatment were moved to the study pen in groups of 44 cows, but no new cows entered the AIAO pen until the end of the replicate. At the end of each replicate, a new TRD and AIAO group started but pens were switched. Cows were milked thrice daily and monthly milk yield, fat and protein contents, and somatic cell count data were recorded up to 305 d postpartum. Plasma nonesterified fatty acid concentration was measured weekly from d -18±3 to 24±3 and plasma ß-hydroxybutyrate was measured weekly from d 3±3 to 24±3. Cows were examined on d 1, 4±1, 7±1, 10±1, and 13±1 for diagnosis of uterine diseases and had their ovaries scanned by ultrasound on d 39±3 and 53±3 to determine resumption of ovarian cycles. Average stocking density was reduced for the AIAO (71.9%) treatment compared with the TRD (86.9%) treatment. Treatment did not affect the incidences of retained fetal membranes (TRD=10.9, AIAO=11.6%), metritis (TRD=16.7, AIAO=19.8%), and acute metritis (TRD=1.7, AIAO=3.6%). Concentrations of nonesterified fatty acids (TRD=80.4±8.2, AIAO=62.9±8.5 µmol/L) and ß-hydroxybutyrate (TRD=454.4±10.9, AIAO=446.1±11.1 µmol/L) were not different between treatments. Percentages of cows that resumed ovarian cycles by d 39±3 (TRD=70.8, AIAO=63.1%) and 53±3 (TRD=90.1, AIAO=90.2%) were not different between treatments. Similarly, treatment had no effect on rate of removal from the herd {TRD=referent, AIAO [(adjusted hazard ratio (95% confidence interval)]=0.85 (0.63, 1.15)} or rate of pregnancy [TRD=referent, AIAO=1.07 (0.88, 1.30)]. Finally, treatment did not affect energy-corrected milk yield (TRD=34.4±0.6, AIAO=34.3±0.7 kg/d). In conditions of adequate feed bunk space, the AIAO treatment did not improve health, metabolic, reproductive, or productive parameters compared with the TRD treatment.

Comparison of innate immune responses and somatotropic axis components of Holstein and Montbéliarde-sired crossbred dairy cows during the transition period.

Objectives were to compare parameters related to innate immune responses and somatotropic axis of Holstein (HO) and Montbéliarde (MO)-sired crossbred cows during the transition from late gestation to early lactation. Cows (40 HO and 47 MO-sired crossbred) were enrolled in the study 45d before expected calving date (study d 0=calving). Polymorphonuclear leukocytes (PMNL) isolated from blood samples collected weekly from study d -7 to 21 and on study d 42 were used for determination of percentage of PMNL positive for phagocytosis (PA+) and oxidative burst (OB+), intensity of PA and OB, percentage of PMNL expressing CD18 (CD18+) and L-selectin (LS+), and intensity of CD18 and LS expression. Blood was sampled weekly from study d -7 to 14 and on study d 28, 42, and 56 for determination of insulin, growth hormone (GH), leptin, and insulin-like growth factor (IGF)-1 concentrations. Blood sampled weekly from study d -14 to 21 and on study d 42 was used to determine cortisol concentration. Liver biopsies were performed on study d -14, 7, 14, and 28 for determination of mRNA expression for insulin receptor B (IRB), total GH receptor (GHRtot), GHR variant 1A (GHR1A), and IGF-1. Data were analyzed by ANOVA for repeated measures or by ANOVA using the GLM procedure of SAS (SAS Institute Inc., Cary, NC). Intensity of CD18 expression was greater in PMNL from crossbred cows compared with PMNL from HO cows [1,482.1 ± 82.3 vs. 1,286.6 ± 69.8 geometric mean fluorescence intensity (GMFI)]. Furthermore, among HO cows, the percentage of PA+ PMNL on study d -7 (64.4 ± 5.2%) tended to be greater than on study d 0 (57.1 ± 5.1%), but no differences in percentage of PA+ PMNL between study d -7 and 0 were observed in crossbred cows. Similarly, intensity of PA in PA+ PMNL from HO cows decreased from study d -7 to 0 (4,750.6 ± 1,217.0 vs. 1,964.7 ± 1,227.9 GMFI), but no changes in intensity of PA in PA+ PMNL from crossbred cows were observed. On study d 0, intensity of PA tended to be reduced in PA+ PMNL from HO cows compared with PA+ PMNL from crossbred cows (1,964.7 ± 1,227.9 vs. 4,688.1 ± 1,271.8 GMFI). Concentrations of GH (7.4 ± 0.4 vs. 5.1 ± 0.4 ng/mL) and cortisol (9.5 ± 0.8 vs. 7.1 ± 0.8 ng/mL) were greater for HO than for crossbred cows. Crossbred cows had improved innate immune responses compared with HO cows, as determined by a lack of decrease in intensity of PA on the day of calving, which may result in improved health. Furthermore, HO cows appeared to be less sensitive to the negative feedback of IGF-1 on GH secretion because cows from both breeds had similar IGF-1 concentrations but MO-sired crossbred cows had greater GH concentrations.

Evaluation of reproductive and economic outcomes of dairy heifers inseminated at induced estrus or at fixed time after a 5-day or 7-day progesterone insert-based ovulation synchronization protocol.

The objectives of the current experiment were to evaluate the reproductive performance and economic outcome of 3 synchronization strategies for first artificial insemination (AI) of dairy heifers. Holstein heifers from 2 herds (site A, California, n=415; site B, Idaho, n=425) were assigned to 1 of 3 treatments. Heifers assigned to the AI on estrus (AIE) treatment received an injection of 25mg of PGF(2α) at enrollment (d 0) and every 11 d thereafter until AI occurred. Heifers assigned to the CIDR5 treatment received a controlled internal drug release insert (CIDR) containing 1.38 g of progesterone, which was removed 5 d later concomitantly with an injection of 25mg of PGF(2α), and received fixed-time AI (TAI) concomitantly with an injection of 100 µg of GnRH 53 to 60 h later. Heifers assigned to the CIDR7 treatment received a CIDR insert, which was removed 7 d later concomitantly with an injection of 25mg of PGF(2α), and received TAI concomitantly with an injection of 100 µg of GnRH 53 to 60 h later. Heifers were observed for estrus and inseminated up to 98 and 73 d after enrollment in sites A and B, respectively. Thereafter, heifers were moved to pens with bulls and considered failure to conceive to AI if still not pregnant at the end of the observation period. Economic outcomes were based on cost of synchronization protocol (CIDR treatment=$11, PGF(2α) or GnRH treatments=$2.5/treatment, estrous detection=$0.80/heifer per day), rearing cost ($2.75/heifer per day), and economic loss if a heifer did not conceive to first AI ($150). Input cost of the reproductive programs=synchronization protocol cost + semen cost + rearing cost + replacement cost. Pregnancy per AI (P/AI) 38 ± 3 d after first AI was greatest for AIE heifers (61.1%) followed by CIDR5 (44.8%) and CIDR7 (35.7%) heifers. Furthermore, P/AI 73 ± 7 d after first AI was greatest for AIE (58.8%) and tended to be greater for CIDR5 (42%) than for CIDR7 (34.1%) heifers. The percentage of heifers that had spontaneous luteolysis from CIDR insertion to CIDR removal was reduced for CIDR5 compared with CIDR7 (13.8 vs 31.8%). Pregnancy rate was greatest for AIE heifers but did not differ between CIDR5 [adjusted hazard ratio (95% confidence interval)=0.75 (0.63, 0.90)] and CIDR7 [adjusted hazard ratio (95% confidence interval)=0.65 (0.54, 0.77)] heifers. Consequently, rearing cost and input cost of AIE heifers ($67.1 ± 4.4 and -$107.1 ± 7.0, respectively) were reduced compared with CIDR5 ($86.9 ± 5.1 and -$143.4 ± 8.1, respectively) and CIDR7 ($98.3 ± 5.1 and -$156.5 ± 8.2, respectively) heifers, but no differences were observed between CIDR5 and CIDR7 heifers.